Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
2.260
-0.030 (-1.31%)
At close: Mar 13, 2026, 4:00 PM EDT
2.270
+0.010 (0.44%)
After-hours: Mar 13, 2026, 7:50 PM EDT

Tempest Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
13.6113.5511.6612.119.824.91
Research & Development
22.8128.4817.522.5317.1714.39
Total Operating Expenses
36.4242.0329.1634.6426.9919.3
Operating Income
-36.42-42.03-29.16-34.64-26.99-19.3
Interest Income
1.272.822.562.171.250.09
Other Non-Operating Income (Expense)
0.360.18-0.33-1.07-1.320.09
Total Non-Operating Income (Expense)
1.6332.231.1-0.070.18
Pretax Income
-34.78-39.03-26.93-33.54-27.05-19.12
Net Income
-36.05-41.84-29.49-35.71-28.3-19.21
Net Income to Common
-36.05-41.84-29.49-35.71-28.3-19.21
Shares Outstanding (Basic)
421100
Shares Outstanding (Diluted)
421100
Shares Change (YoY)
114.09%80.99%33.49%204.70%709.62%-48.77%
EPS (Basic)
-10.04-19.50-24.83-40.17-97.11-533.39
EPS (Diluted)
-10.04-19.50-24.83-40.17-97.11-533.39
Free Cash Flow
-33.4-33.46-27.53-31.63-26.09-19.07
Free Cash Flow Per Share
-9.01-15.59-23.21-35.61-89.49-529.46
EBITDA
-36.17-41.64-28.78-34-26.61-18.96
EBIT
-36.42-42.03-29.16-34.64-26.99-19.3
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q